| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue from customers | - | - | 12 | 74 |
| Research and development | 1,120 | 2,735 | 1,414 | 2,896 |
| General and administrative | 5,674 | 2,268 | 3,602 | 3,432 |
| Total operating expenses | 6,794 | 5,003 | 5,016 | 6,328 |
| Eloc commitment fee | - | - | -1,095 | - |
| Loss from operations | -6,794 | -5,003 | -5,004 | -6,254 |
| Change in fair value of convertible rights | - | - | -179 | - |
| Warrant issuance costs | - | 129 | - | - |
| Gain on change in fair value of warrant liabilities | - | -1,824 | 103 | - |
| Interest income | - | 4 | 28 | 28 |
| Loss on extinguishment | - | -994 | - | - |
| R&d tax incentive | 389 | 421 | 956 | 811 |
| Foreign exchange gains/(losses) | -13 | 41 | -326 | -5 |
| Interest income | -5 | 132 | 171 | - |
| Share of earnings (loss) of joint venture | 6 | - | - | - |
| Total other income, net | 387 | 1,035 | -890 | 834 |
| Loss before income tax expense | -6,407 | -3,968 | -5,894 | -5,420 |
| Net loss | -6,407 | -3,968 | -5,894 | -5,420 |
| Currency translation adjustment, net of tax | 223 | -88 | -414 | 339 |
| Total comprehensive loss | -6,184 | -4,056 | -6,308 | -5,081 |
| Net loss per share basic (in dollars per share) | -0.02 | -0.2 | -0.33 | -0.29 |
| Net loss per share diluted (in dollars per share) | -0.02 | -0.2 | -0.33 | -0.29 |
| Weighted average number of shares outstanding, basic (in shares) | 310,309,659 | 19,632,539 | 17,624,422 | 17,642,832 |
| Weighted average number of shares outstanding, diluted (in shares) | 310,309,659 | 19,632,539 | 17,624,422 | 17,642,832 |
Incannex Healthcare Inc. (IXHL)
Incannex Healthcare Inc. (IXHL)